Scholar Rock Holding (SRRK) Assets Average (2018 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Assets Average of $469.8 million in Q1 2026, up 15.14% quarter-over-quarter from $408.0 million in Q4 2025, and up 6.46% on a YoY basis from $441.2 million in Q1 2025.
Scholar Rock Holding (SRRK) Assets Average (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Assets Average history runs 9 years deep, the most recent figure standing at $469.8 million for Q1 2026.
- In Q1 2026, Assets Average rose 6.46% year-over-year to $469.8 million; the TTM figure through Mar 2026 stood at $469.8 million (up 6.46% YoY), while the FY2025 annual figure was $439.6 million, up 11.86% from the prior year.
- Assets Average was $469.8 million for Q1 2026 at Scholar Rock Holding, up from $408.0 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $469.8 million in Q1 2026 to a low of $203.0 million in Q3 2024.
- Historically, Assets Average has averaged $337.2 million across 5 years, with a median of $336.4 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Assets Average sank 34.24% in 2023, then soared 85.16% in 2025.
- A 5-year view of Assets Average shows it stood at $374.2 million in 2022, then dropped by 24.95% to $280.9 million in 2023, then increased by 16.44% to $327.0 million in 2024, then climbed by 24.76% to $408.0 million in 2025, then rose by 15.14% to $469.8 million in 2026.
- The last three Assets Average figures came in at $469.8 million (Q1 2026), $408.0 million (Q4 2025), and $375.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 26.03 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 40.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 660.38 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 469.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 469.76 Mn |
| Dec 31, 2025 | 408.00 Mn |
| Sep 30, 2025 | 375.88 Mn |
| Jun 30, 2025 | 373.80 Mn |
| Mar 31, 2025 | 441.24 Mn |
| Dec 31, 2024 | 327.03 Mn |
| Sep 30, 2024 | 203.00 Mn |
| Jun 30, 2024 | 247.08 Mn |
| Mar 31, 2024 | 289.16 Mn |
| Dec 31, 2023 | 280.86 Mn |
| Sep 30, 2023 | 267.79 Mn |
| Jun 30, 2023 | 299.81 Mn |
| Mar 31, 2023 | 336.44 Mn |
| Dec 31, 2022 | 374.24 Mn |
| Sep 30, 2022 | 407.22 Mn |
| Jun 30, 2022 | 345.05 Mn |
| Mar 31, 2022 | 285.21 Mn |
| Dec 31, 2021 | 301.42 Mn |
| Sep 30, 2021 | 315.22 Mn |
| Jun 30, 2021 | 346.32 Mn |